Loading…
Loading…
CTEV does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for CTEV and 80,000+ other tickers.
See exactly how CTEV's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CTEV and 80,000+ other tickers.
Claritev Corporation, together with its affiliated companies, provides advanced data analytics and technology-enabled services focused on cost management, payment optimization, and revenue assurance for the healthcare sector across the United States. The company offers a suite of services designed to reduce medical expenses. This includes analytics-driven solutions that utilize sophisticated algorithms and data insights to pinpoint billing overcharges, subsequently assisting with or recommending appropriate reimbursement negotiations. Additionally, their network-focused services secure…
Claritev (NYSE: CTEV - Get Free Report) SVP Tiffani Misencik sold 5,812 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $23.81, for a total transaction of $138,383.72. Following the sale, the senior vice president directly owned 107,917 shares of the company's stock, valued at
MCLEAN, Va., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data, and insights company, today announced that its Board of Directors (“Board”) has appointed Jennifer (Jenni) Main as a director, effective today, filling a newly created directorship on the Board.
MCLEAN, Va., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a healthcare technology, data, and insights company focused on making healthcare more affordable, transparent, and fair for all, announced today that it will release its third quarter fiscal year 2026 financial results prior to market open on Monday, November 9, 2026, and hold a conference call at 8:00 am Eastern Time.
Schrodinger (NASDAQ: SDGR - Get Free Report) and Claritev (NYSE: CTEV - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends. Profitability This table compares Schrodinger and Claritev's net margins, return
Claritev is showing early signs of a turnaround, with revenue and bookings growth supporting a Buy rating and a $34 price target (+40% upside). CTEV's 2027 earnings growth is critical, as high leverage (net debt $4.69B) and modest FCF ($5–15M in 2026) amplify financial risk. Revenue growth is concentrated in Claims Intelligence; broad-based margin recovery and operational leverage are needed to validate the investment thesis.